EMA asks for more in­for­ma­tion af­ter safe­ty sig­nal aris­es for GLP-1s, semaglu­tide in thy­roid can­cer

The Eu­ro­pean Med­i­cines Agency is con­cerned there could be a po­ten­tial link be­tween thy­roid can­cer and the use of glucagon-like pep­tide-1 (GLP-1) re­cep­tor ag­o­nists, which in­cludes med­i­cines con­tain­ing No­vo Nordisk’s semaglu­tide like Ozem­pic, Ry­bel­sus and We­govy.

The agency raised a safe­ty sig­nal last month over the class of drugs and re­quest­ed more in­for­ma­tion from No­vo Nordisk, As­traZeneca, Sanofi and Eli Lil­ly, Reuters re­port­ed to­day af­ter a Dan­ish me­dia out­let first pub­lished the sig­nal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER